NCT06055075 2025-07-14
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1/2 Completed
Clinical Trials
5 trialsNCT03450057 2024-03-29
DARE
Hellenic Society of Hematology
Phase 2 Completed
NCT04136756 2023-06-15
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Nektar Therapeutics
Phase 1 Completed
NCT03000452 2018-10-16
FUSION-MM-005
Celgene
Phase 2 Completed
NCT02116569 2016-09-26
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Completed